NCT01190007

Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

A Multi-Center, Open Label Study To Evaluate Long Term Safety Of Caduet In Patient With Both Of Hypertension And Hypercholesterolemia, Or With Both Of Angina Pectoris And Hypercholesterolemia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 159 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension and hypercholesterolemia, or with both angina pectoris and hypercholesterolemia.

Conditions

• Hypertension
• Hypercholesterolemia
• Angina Pectoris

Interventions

Type	Name	Description
DRUG	Caduet	One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks

Timeline

• Start date: 2010-08-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2010-08-27
• Last updated: 2021-01-28
• Results posted: 2012-12-03

Locations

20 sites across 1 country: Japan